MDCO stock: buy or sell?

MDCO stock price: $84.90 -0.07% At close on January 3rd, 2020

Updated on:
January 3rd, 2020


After reaching all time highs on January, The Medicines remained steady -0.07% on January to $84.90. January broke a green streak of 4 days.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.

Should I buy MDCO stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that fits your character as inversor. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, 2 buy setups are elegible for The Medicines stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is The Medicines stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for MDCO stock for the last 30 days.

MDCO stock analysis

Daily outlook

After climbing for 4 days, January The Medicines remained constant a tight -0.07%, closing at $84.90.

After several days of continuous rises in past weeks, The Medicines remained stable -0.07% to $84.90. Since price and SMA100d lines crossed up on August, MDCO climbed $52.07 (158.60%). Even closing in lows, the session peaked to new all time highs at $84.98.

MDCO stock chart (daily)

Weekly outlook

The Medicines shares remained steady 0.14% late December 2019 and topped a new all time high at $84.98. Late November 2019 MDCO climbed an amazing 18.59% in just one week. For 5 weeks in a row, price soared and marked a profit of 1.02%. By mid November 2019 MDCO plummed a hair-raising -5.83% in just one week.

The Medicines stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since SMA20d and SMA40w crossed up late May 2019, MDCO price climbed $51.91 per share (157.35%). Since price and SMA40w lines crossed up early April, MDCO climbed $56.95 (203.76%).

MDCO stock chart (weekly)

MDCO stock price history

MDCO IPO was on August 8th, 2000 at $17.94 per share1. Since then, MDCO stock grew a 373.20%, with a yearly average of 19.60%. If you had invested right after MDCO's IPO a $1,000 in MDCO stock in 2000, it would worth $3,732.00 today.

1: Adjusted price after possible price splits or reverse-splits.

MDCO stock historical price chart

MDCO stock reached all-time highs on January with a price of $84.98.

MDCO stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price prediction for The Medicines stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

The Medicines presented pretty good results for 2018-Q4 on February. The Medicines escalated Earnings per Share (EPS) by 15.50%, beating analysts consensus of $-0.58. The Medicines posted $-0.67.
MDCO earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, The Medicines annual turnover plunged a chilling -86.30% to $6.14 million dollars from $44.79 marked in 2017. Similarly, its earnings margin (compared to revenues) collapsed to -2,006.45%, that is $-123.16 million.

MDCO annual Sales and Income evolution
2013$688 M-$16 M2.3%-
2014$724 M5.31%$-32.21 M-4.4%-307.67%
2015$309 M-57.34%$-352.76 M-114.2%995.18%
2016$168 M-45.69%$-119.12 M-71.0%-66.23%
2017$45 M-73.31%$-708.37 M-1581.6%494.68%
2018$6.14 M-86.30%$-123.16 M-2006.5%-82.61%

Quarterly financial results

The Medicines posted $0.00 M in sales for 2018-Q4, a -100.00% less compared to previous quarter. Reported quarter income marked $-42.47 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was 1,685.88%. When comparing sales to same quarter last year, The Medicines sales marked a bloodcurdling slide and plummed a -100.00%.
MDCO quarterly Sales and Income evolution
2017-Q2$18.74 M-$-397.27 M-2119.9%-
2017-Q3$16.87 M-9.97%$-30.18 M-178.9%-92.40%
2017-Q4$8.60 M-49.05%$-178.26 M-2074.0%490.75%
2018-Q1$7.77 M-9.59%$29.15 M375.1%-116.35%
2018-Q2$1.67 M-78.55%$-54.20 M-3251.2%-285.93%
2018-Q3$-3.30 M-297.96%$-55.63 M1685.9%2.65%

The Medicines ownership

When you are planning to buy shares of a company, it's always worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For The Medicines, of all outstanding shares are owned by its staff.

The following table compares ownership indicators for other stocks related to The Medicines:

Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

MDCO summary

Friday, January 3rd, 2020
Day range$84.88 - $84.98
Previous close$84.96
Session gain-0.07%
Average true range$0.17
50d mov avg$71.86
100d mov avg$59.07
200d mov avg$46.19
Daily pattern
Weekly pattern lt06a

The Medicines performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare The Medicines performance to :
MDCOThe Medicines65.98%129.65%356.21%

The Medicines competitors

Unfortunately, we could not find any public company that could be defined as The Medicines competitor. This doesn't mean The Medicines does not have any competitor in the market, it's just we could not detected it.